GlobeNewswire Inc.T3·5mo ago
ARTV Artiva Biotherapeutics, Inc. Common Stock
XNAS
6.16
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ARTV
$6.16
—
Key stats
$6.16
- 52-Week Range
- $2.96 – $14.53
- YTD
- +45.63%
- IV Rank (30D)
- 5.94
- Straddle Price
- $4.90
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.3B
- Open
- $6.15
- Day Range
- $5.95 – $6.25
- Volume
- 487,078
- Prev Close
- $6.15
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.87 |
| Cost of Equity (CAPM) | 15.23% (VRP-adj) |
| WACC | 15.39% |
| Volatility Risk Premium | +161.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -26.1% |
| Book / Price | 199.7% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $8.70 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $6.56 |
| Bollinger Width / SMA20 | 420.1% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $0B |
Peers used for multiples: ABEO, CLDX, DCTH, KYTX
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$32.10
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $32.10 | 100% | median 2.6× · 4 peers |
| Peer P/S | n/a | 0% | median 9.9× · 3 peers |
| Market Anchor (SMA50) | $8.70 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $6.05 | 0% | 5 strikes · skew +0.32 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 115
- List Date
- 2024-07-19
- CIK
- 0001817241
- Next Earnings
- 2026-11-11 (Pre-Market)
- EPS Forecast
- ($0.54) (3 est.)
- Headquarters
- San Diego, CA
- Homepage
- https://www.artivabio.com
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | -49.05% | -8.04% | -28.54% |
| Feb | -- | -15.13% | 39.23% | 12.05% |
| Mar | -- | -23.47% | 11.61% | -5.93% |
| Apr | -- | -20.33% | 51.70% | 15.69% |
| May | -- | -18.57% | -26.57% | -22.57% |
| Jun | -- | -22.16% | 30.03% | 3.94% |
| Jul | -1.67% | 96.08% | 2.54% | 32.32% |
| Aug | -0.43% | 11.31% | 5.02% | 5.30% |
| Sep | 40.33% | -7.12% | -36.88% | -1.22% |
| Oct | -34.24% | 42.81% | -9.28%* | -0.24% |
| Nov | 19.22% | -0.27% | -- | 9.47% |
| Dec | -20.94% | 23.63% | -- | 1.34% |
| Total | -14.84% | -40.35% | 27.64% | -9.18% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $6.56
SMA 50: $8.70
SMA 200: $8.04
Current: $6.16
EMA 12: $6.37
EMA 26: $7.03
MACD: -0.6567 | Signal: 0.1065
BEARISH
ADX (14): 49.34
STRONG TREND
+DI: 14.36
−DI: 31.45
Momentum Oscillators
RSI (14): 34.39
NEUTRAL
Stoch %K: 25.91
Stoch %D: 32.85
Williams %R: -73.51
Volume & Volatility
BB Upper: $7.47
BB Lower: $5.66
NEUTRAL
OBV: 124,744,001
Vol SMA 20: 451,292
Vol ROC: 95.92%
ATR: $0.44
True Range: $0.30
HV 20: 65.3%
HV 30: 73.1%
HV 60: 62.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is the LLM Stock Analysis report for ARTV:
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers: Positive news sentiment, momentum signals, and recent appointments to key positions.
Primary Risks: High volatility, potential pullback from overbought conditions, and earnings uncertainty.
Investment Thesis: ARTV's strong technical signals, positive news sentiment, and recent appointments suggest a bullish outlook. However, high volatility and potential pullbacks should be monitored.
Recent News Sentiment Impact: The recent news headlines have had a strongly positive impact on ARTV's stock price, contributing to its overall bullish momentum.
Technical Analysis
Trend Direction: Bullish (Short-term: Upward, Medium-term: Uptrend, Long-term: Uptrend)
Support/Resistance Levels:
- Lower Bollinger Band: $10.88 (support)
- Upper Bollinger Band: $12.00 (resistance)
- SMA 20: $11.44 (resistance)
Momentum Signals: RSI Interpretation: Neutral (50.99), indicating a potential consolidation phase.
MACD Signal: Bullish (0.18 / Signal: -0.11 / Histogram: 0.29), suggesting ongoing upward momentum.
Bollinger Bands Position: Squeeze (neutral), indicating market uncertainty and volatility.
Volume Analysis:
- Volume SMA 20: 279645.72 (above average)
- On-Balance Volume (OBV): 130329336.61 (strongly positive)
- Volume Rate of Change: -15.46% (negative, but still above average)
News & Sentiment Analysis
Recent Headlines Summary: ARTV has had a string of positive news headlines regarding appointments to key positions and market developments.
Sentiment Assessment: The overall sentiment is POSITIVE, driven by the recent news headlines and ARTV's strong technical signals.
Catalyst Identification: Upcoming events include the 25th Annual Needham Virtual Healthcare Conference (April 8) and potential earnings releases.
Market Narrative: The positive news sentiment aligns with the technical signals, suggesting a bullish market narrative for ARTV.
Risk & Volatility Assessment
Risk Assessment: Beta: 2.01 (high risk), indicating volatility greater than the broader market.
Volatility Regime: Current vs historical volatility levels: High (1.83) and increasing, suggesting potential pullbacks.
Options Market Signals: IV Rank: 7.8% (Low - shows if volatility is historically high/low)
Market Context & Positioning
Sector Performance: ARTV's sector (Biotechnology) has been performing well, contributing to its strong technical signals.
Institutional Activity: Volume patterns suggest institutional interest and support for ARTV.
Correlation Analysis: How stock moves relative to market: 0.14 (positive), indicating a relatively strong correlation with the broader market.
Relative Valuation: Position within trading range: Above average, suggesting a potentially overbought condition.
Key Levels & Action Items
Critical Price Levels:
- Support: Lower Bollinger Band ($10.88)
- Resistance: Upper Bollinger Band ($12.00)
Breakout/Breakdown Levels:
- SMA 20 (resistance): $11.44
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches.
Risk Management: Stop-loss levels and position sizing considerations should be carefully evaluated due to ARTV's high volatility.
Note: The report provides an objective analysis of the stock's technical, fundamental, and market conditions.
Generated
News
All ARTV news →
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·8mo ago
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·20mo ago
Earnings History
1 of 1 under expected move
Avg Expected Move
30.71%
Avg Actual Move
4.70%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-08-05 | Pre-Market | 30.71% | 4.70% | 0.15x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ARTV Options Activity & IV Rank
ARTV IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 95.5%
7-DTE IV: —
Expected Move: $4.90
7-DTE Move: $4.90
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 1,544
Put Volume: 3
P/C Volume: 0.002
BULLISH
Call OI: 2,821
Put OI: 3
P/C OI: 0.001
Total OI: 2,824
ATM Options Pricing
ATM Call: $2.45
ATM Put: $2.45
Call %: 39.8%
Put %: 39.8%
Chain Summary
Chain Volume: 1,825
Chain OI: 4,900
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 37th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
37%
vs own history
GEX tilt
-0.88
OI-weighted, today
Vanna tilt
-0.90
δ-sensitivity to IV
Charm tilt
+0.76
δ-decay vs time
Vanna tilt -0.90: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.76: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 144.1% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)5.9LowOct 26
Straddle Price (30 DTE)$4.90Oct 26
Beta Analysis
Risk Metrics
Beta: 1.7995
Alpha: 67.52%
Correlation: 0.1674
R-Squared: 2.8%
Stock Volatility: 137.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ARTV
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Viking Global Hedge fund Andreas Halvorsen | $25.3M | #81 of 90 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $5.9M | #1969 of 6285 | +3739.8% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $1.5M | #2137 of 3138 | +88.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ARTV Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 28,254,358 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
ARTV Insider Trading (Form 4)
Latest: 2026-10-07Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Fred Aslan | Chief Executive Officer | Sell (S) | −23,463 | $7.20 | -$168.9K | EDGAR |
| 2026-10-06 | Subhashis Banerjee | Chief Medical Officer | Sell (S) | −1,099 | $6.84 | -$7.5K | EDGAR |
| 2026-10-06 | Fred Aslan | Chief Executive Officer | Sell (S) | −61,696 | $6.84 | -$421.8K | EDGAR |
| 2026-10-06 | Jennifer Bush | COO, CLO, Compliance Officer | Sell (S) | −8,370 | $6.84 | -$57.2K | EDGAR |
| 2026-10-06 | Christopher Horan | Chief Tech Operations Officer | Sell (S) | −10,340 | $6.84 | -$70.7K | EDGAR |
| 2026-09-15 | Fred Aslan | Chief Executive Officer | Award (A) | +110,000 | — | EDGAR | |
| 2026-09-14 | Laura Stoppel | Director | Grant (A) | +16,250 opt | — | EDGAR | |
| 2026-09-14 | Brian Daniels | Director | Grant (A) | +16,250 opt | — | EDGAR | |
| 2026-09-14 | Alison Moore | Director | Grant (A) | +16,250 opt | — | EDGAR | |
| 2026-09-14 | Elizabeth L Hougen | Director | Grant (A) | +16,250 opt | — | EDGAR | |
| 2026-09-14 | Daniel G. Baker | Director | Grant (A) | +16,250 opt | — | EDGAR | |
| 2026-09-14 | Peter Kolchinsky | Director | Grant (A) | +97,500 opt | — | EDGAR | |
| 2026-09-14 | Fred Aslan | Chief Executive Officer | Award (A) | +45,000 | — | EDGAR | |
| 2026-09-14 | Elaine K. Sorg | Director | Grant (A) | +16,250 opt | — | EDGAR | |
| 2026-09-11 | Gines Diego Miralles | President & Head of R&D | Award (A) | +45,000 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ARTV Insider Holdings
14 insiders · @ $6.16
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Nexus Fund, L.P. | Director | 17,304,626 | $106.60M | $694.21M | 7 | 2026-07-31 |
| 2 | RA Capital Healthcare Fund LP | Director | 16,817,543 | $103.60M | $349.8K | 1 | 2026-07-23 |
| 3 | GC Cell Corp | 10%+ Owner | 5,999,703 | $36.96M | $33.00M | 1 | 2026-05-28 |
| 4 | Fred Aslan | Chief Executive Officer | 1,519,606 | $9.36M | -$2.04M | 15 | 2026-10-07 |
| 5 | Jennifer Bush | COO, CLO, Compliance Officer | 366,159 | $2.26M | -$230.0K | 10 | 2026-10-06 |
| 6 | Christopher Horan | Chief Tech Operations Officer | 312,744 | $1.93M | -$249.4K | 10 | 2026-10-06 |
| 7 | Peter Kolchinsky | Director | 264,571 | $1.63M | $458.59M | 3 | 2026-09-14 |
| 8 | Thad Allen Huston | Chief Financial Officer | 220,000 | $1.36M | $0 | 1 | 2026-03-10 |
| 9 | Subhashis Banerjee | Chief Medical Officer | 169,848 | $1.05M | -$187.1K | 8 | 2026-10-06 |
| 10 | Heather Raymon | SVP, Research and Development | 148,228 | $913.1K | -$27.9K | 7 | 2026-05-19 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ARTV Board & Officers
As of SEC filings through Oct 7, 2026Directors 13
- Brian Daniels · since Jul 18, 2024
- Elizabeth L Hougen · since Jul 18, 2024
- Fred Aslan · since Jul 18, 2024
- Laura Stoppel · since Jul 18, 2024
- Peter Kolchinsky · since Jul 18, 2024
- RA Capital Healthcare Fund LP (entity) · since Jul 18, 2024
- RA Capital Nexus Fund, L.P. (entity) · since Jul 18, 2024
- Ra Capital Management, L.p. (entity) · since Jul 18, 2024
- Rajeev M. Shah · since Jul 18, 2024
- RA Capital Nexus Fund III, L.P. (entity) · on file since Jul 2024
- Alison Moore · since Oct 21, 2024
- Daniel G. Baker · since Jan 28, 2025
- Elaine K. Sorg · since Feb 18, 2026
Officers 6
- Fred Aslan · Chief Executive Officer · listed since May 2026
- Gines Diego Miralles · President & Head of R&D · listed since May 2026
- Jennifer Bush · COO, CLO, Compliance Officer · listed since May 2026
- Christopher Horan · Chief Tech Operations Officer · since Jul 18, 2024
- Subhashis Banerjee · Chief Medical Officer · since Apr 8, 2025
- Heather Raymon · SVP, Research and Development · since Jul 18, 2024
10% owners 6
- GC Cell Corp (entity) · since Jul 18, 2024
- GC Corp. (entity) · since Jul 18, 2024
- Peter Kolchinsky · since Jul 18, 2024
- RA Capital Healthcare Fund LP (entity) · since Jul 18, 2024
- Ra Capital Management, L.p. (entity) · since Jul 18, 2024
- Rajeev M. Shah · since Jul 18, 2024
Changes in the last 10 years (53)
| May 19, 2026 | Jennifer Bush listed as COO, CLO, Compliance Officer (previously COO, CLO, Secy, Compliance Off) in SEC filings |
| May 19, 2026 | Gines Diego Miralles first listed as President & Head of R&D in an SEC filing |
| May 19, 2026 | Fred Aslan listed as Chief Executive Officer (previously President and CEO) in SEC filings |
| May 18, 2026 | The company announced the departure of Thad Allen Huston as Chief Financial Officer in an SEC filing |
| May 18, 2026 | The company announced the departure of Gines Diego Miralles from the board in an SEC filing |
| Feb 18, 2026 | Thad Allen Huston became Chief Financial Officer |
| Feb 18, 2026 | Elaine K. Sorg became a director |
| Apr 8, 2025 | Subhashis Banerjee became Chief Medical Officer |
| Jan 28, 2025 | Daniel G. Baker became a director |
| Oct 21, 2024 | Alison Moore became a director |
| Jul 24, 2024 | RA Capital Nexus Fund III, L.P. first on file as a director |
| Jul 24, 2024 | 5AM Opportunities II, L.P. first on file as a 10% owner |
| Jul 24, 2024 | 5AM Opportunities II (GP), LLC first on file as a 10% owner |
| Jul 22, 2024 | venBio Global Strategic Fund III, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2024 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2024 | Venbio Global Strategic Gp III, Ltd reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2024 | Venbio Global Strategic Gp III, L.p. reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2024 | Robert J Adelman reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2024 | Corey S Goodman reported in an SEC filing no longer being a 10% owner |
| Jul 18, 2024 | venBio Global Strategic Fund III, L.P. became a 10% owner |
| Jul 18, 2024 | Yong-Jun Huh became a director |
| Jul 18, 2024 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. became a 10% owner |
| Jul 18, 2024 | Venbio Global Strategic Gp III, Ltd became a 10% owner |
| Jul 18, 2024 | Venbio Global Strategic Gp III, L.p. became a 10% owner |
| Jul 18, 2024 | Thorsten Graef became Chief Medical Officer |
| Jul 18, 2024 | Robert J Adelman became a 10% owner |
| Jul 18, 2024 | Rajeev M. Shah became a director |
| Jul 18, 2024 | Rajeev M. Shah became a 10% owner |
| Jul 18, 2024 | Ra Capital Management, L.p. became a director |
| Jul 18, 2024 | Ra Capital Management, L.p. became a 10% owner |
| Jul 18, 2024 | RA Capital Nexus Fund, L.P. became a director |
| Jul 18, 2024 | RA Capital Healthcare Fund LP became a director |
| Jul 18, 2024 | RA Capital Healthcare Fund LP became a 10% owner |
| Jul 18, 2024 | Peter Kolchinsky became a director |
| Jul 18, 2024 | Peter Kolchinsky became a 10% owner |
| Jul 18, 2024 | Neha Krishnamohan became Chief Financial Officer |
| Jul 18, 2024 | Laura Stoppel became a director |
| Jul 18, 2024 | Laura Bessen became a director |
| Jul 18, 2024 | Kush Parmar became a 10% owner |
| Jul 18, 2024 | Jennifer Bush became COO, CLO, Secy, Compliance Off |
| Jul 18, 2024 | Heather Raymon became SVP, Research and Development |
| Jul 18, 2024 | Gines Diego Miralles became a director |
| Jul 18, 2024 | GC Corp. became a 10% owner |
| Jul 18, 2024 | GC Cell Corp became a 10% owner |
| Jul 18, 2024 | Fred Aslan became a director |
| Jul 18, 2024 | Fred Aslan became President and CEO |
| Jul 18, 2024 | Elizabeth L Hougen became a director |
| Jul 18, 2024 | Corey S Goodman became a 10% owner |
| Jul 18, 2024 | Christopher Horan became Chief Tech Operations Officer |
| Jul 18, 2024 | Brian Daniels became a director |
| Jul 18, 2024 | Andrew J. Schwab became a 10% owner |
| Jul 18, 2024 | 5AM Ventures VI, L.P. became a 10% owner |
| Jul 18, 2024 | 5AM Partners VI, LLC became a 10% owner |
Not reported recently (10)
- Neha Krishnamohan · Last reported as Chief Financial Officer in an SEC filing dated Nov 17, 2025
- Thorsten Graef · Last reported as Chief Medical Officer in an SEC filing dated Feb 28, 2025
- Andrew J. Schwab · Last reported as a 10% owner in an SEC filing dated Jul 24, 2024
- 5AM Ventures VI, L.P. · Last reported as a 10% owner in an SEC filing dated Jul 24, 2024
- Kush Parmar · Last reported as a 10% owner in an SEC filing dated Jul 24, 2024
- 5AM Partners VI, LLC · Last reported as a 10% owner in an SEC filing dated Jul 24, 2024
- 5AM Opportunities II (GP), LLC · Last reported as a 10% owner in an SEC filing dated Jul 24, 2024
- 5AM Opportunities II, L.P. · Last reported as a 10% owner in an SEC filing dated Jul 24, 2024
- Yong-Jun Huh · Last reported as a director in an SEC filing dated Jul 22, 2024
- Laura Bessen · Last reported as a director in an SEC filing dated Jul 18, 2024
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ARTV Proposed Insider Sales (Form 144)
Latest: 2026-10-06
? Form 144 Guide
Last 30d:
1 filing
· $246K notice value
· Last 90d:
4 filings
· $610K notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
FRED ASLAN (2, $508K) · SUBHASHIS BANERJEE (2, $102K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-06 | FRED ASLAN | Director, Officer | 34,465 | $245.7K | 2026-10-06 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-08 | FRED ASLAN | Director, Officer | 23,429 | $262.2K | 2026-09-08 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-27 | SUBHASHIS BANERJEE | Officer | 7,818 | $92.0K | 2026-08-27 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-18 | SUBHASHIS BANERJEE | Officer | 833 | $9.8K | 2026-08-18 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-18 | Subhashis Banerjee | Officer, Director | 7,000 | $64.5K | 2026-05-18 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-05-18 | Heather Raymon | Officer, Director | 3,500 | $32.3K | 2026-05-18 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-05-18 | Fred Aslan, M.D. | Officer, Director | 28,000 | $258.2K | 2026-05-18 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-05-18 | Christopher P. Horan | Officer, Director | 7,500 | $69.2K | 2026-05-18 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-05-18 | Jennifer Bush | Officer, Director | 9,000 | $83.0K | 2026-05-18 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2025-12-15 | FRED ASLAN | Director, Officer | 12,749 | $42.1K | 2025-12-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
24 ETFs hold ARTV
24 shown · $14.45M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $5.0M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $2.9M | $74.6B | 2026-10-23 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $1.6M | — | 2026-09-30 |
| 4 | SURI Simplify Propel Opportunities ETF | Nport | 1.27% | $983,144 | — | 2026-06-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $906,209 | $13.9B | 2026-10-23 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $799,241 | — | 2026-09-30 |
| 7 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.04% | $777,360 | — | 2026-10-23 |
| 8 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.03% | $358,484 | $1.2B | 2026-10-23 |
| 9 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.00% | $307,955 | $13.7B | 2026-10-23 |
| 10 | FSML Franklin Small Cap Enhanced ETF | Franklin | 0.18% | $272,444 | $150.3M | 2026-10-26 |
| 11 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.00% | $168,670 | — | 2026-10-23 |
| 12 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $93,507 | — | 2026-09-30 |
| 13 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $87,422 | $3.2B | 2026-10-23 |
| 14 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $57,424 | — | 2026-10-26 |
| 15 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $52,257 | — | 2026-10-23 |
| 16 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.00% | $41,018 | — | 2026-09-30 |
| 17 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $18,628 | — | 2026-10-23 |
| 18 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $13,934 | — | 2026-09-30 |
| 19 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $6,819 | — | 2026-10-26 |
| 20 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $5,236 | — | 2026-10-26 |
| 21 | FSEG Fidelity Enhanced Small Cap Growth ETF | Fidelity | 0.05% | $3,911 | $7.6M | 2026-10-23 |
| 22 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $3,678 | — | 2026-10-26 |
| 23 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $142 | — | 2026-10-26 |
| 24 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.00% | $49 | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-3.30
TTM Revenue
—
TTM Net Income
$-90.82M
TTM Op. Cash Flow
$-75.23M
Quarterly figures (2 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-25.00M | $-0.63 | $-20.36M |
| Q2 '25 | 2025-06-30 | — | $-21.25M | $-0.87 | $-22.98M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.50
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-26.1%
ROA
-24.6%
Div Yield
0.00%
FCF Yield
-43.23%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$174.05M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.30M
SI % of Float
16.84%
Days to Cover
3.67
Short Vol Ratio
79.4%
Free Float
13.64M
Float %
27.9%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14